🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

155 results for “control” Clear

  1. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Australia Pty Ltd

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  2. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  3. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  4. Diagnóstico prick Dermatophagoides farinae 40 HEP/ml, Diagnóstico prick control positivo, Diagnóstico prick Dermatophagoides pteronyssinus 40 HEP/ml, Diagnóstico prick control negativo

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  5. Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick Dermatophagoides pteronyssinus, Diagnóstico prick control positivo, Diagnóstico prick control negativo, Diagnóstico prick Dermatophagoides pteronyssinus

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  6. Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick Lepidoglyphus destructor, Diagnóstico prick control negativo, Diagnóstico prick control positivo

    Advanced Accelerator Applications

    Allergies

    phase 2 small molecule active

    1 trial

  7. Diagnóstico prick control positivo, Diagnóstico prick Olea Europae, Diagnóstico prick control negativo, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  8. Diagnóstico prick control positivo, Dignostico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick Blomia tropicalis, Diagnóstico prick control negativo

    Lacuna Pharma Pty Ltd

    Allergies

    phase 2 small molecule active

    1 trial

  9. Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  10. Experimental: CHF6001 3200 μg

    Chiesi Farmaceutici S.p.A.

    Uncontrolled Asthma

    phase 2 small molecule terminated

    1 trial

  11. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Well-Controlled Recurrent Pericarditis

    phase 2 small molecule active

    1 trial

  12. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  13. KT-621, Placebo oral tablet matched to KT-621, KT-621, KT-621

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  14. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA THERAPEUTICS, INC.

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  15. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  17. Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.

    NovoThirteen

    Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.

    phase 2 other active

    1 trial

  18. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  19. Povorcitinib, Placebo, Povorcitinib, Povorcitinib

    Incyte

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial

  20. REGN5381

    Regeneron UK Limited

    Uncontrolled Hypertension

    phase 2 small molecule terminated

    1 trial

  21. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  22. Target-controlled naloxone-infusion

    BRIGHT MINDS BIOSCIENCES INC.

    Central Nervous System Sensitization

    phase 2 small molecule completed

    1 trial

  23. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  24. controlled release carvedilol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources